About: Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
Creator	Shi, Lei Wang, Yan Cao, Yang Wang, Xueli Huang, Mao Ji, Ningfei Wei, Jing Chen, Xiaolin Feng, Ganzhu Shu, Lei Deng, Kaili Huang, Tingrong Wu, Mingjing Yan, Jiaxin Zheng, You Li, Ruyou Niu, Changming
Source	Medline; PMC
abstract	BACKGROUND: COVID-19 is a highly infectious respiratory disease. No therapeutics have yet been proven effective for treating severe COVID-19. OBJECTIVES: To determine whether human umbilical cord mesenchymal stem cell infusion may be effective and safe for the treatment of severe COVID-19. METHODS: Patients with severe COVID-19 were randomly divided into 2 groups: the standard treatment group and the standard treatment plus hUC-MSC infusion group. The incidence of progression from severe to critical illness, 28-day mortality, clinical symptom improvement, time to clinical symptom improvement, hematologic indicators including C-reactive protein, lymphocyte number, and interleukin 6, and imaging changes were observed and compared between the two groups. MEASUREMENTS AND MAIN RESULTS: The incidence of progression from severe to critical illness and the 28-day mortality rate were 0 in the hUC-MSC treatment group, while 4 patients in the control group deteriorated to critical condition and received invasive ventilation; 3 of them died, and the 28-day mortality rate was 10.34%. In the hUC-MSC treatment group, the time to clinical improvement was shorter than that in the control group. Clinical symptoms of weakness and fatigue, shortness of breath, and low oxygen saturation obviously improved beginning on the third day of stem cell infusion and reached a significant difference on day 7. CRP and IL-6 levels were significantly lower from day 3 of infusion, the time for the lymphocyte count to return to the normal range was significantly faster, and lung inflammation absorption was significantly shorter on CT imaging in the hUC-MSC group than in the control group. CONCLUSIONS: Intravenous transplantation of hUC-MSCs is a safe and effective method that can be considered a salvage and priority treatment option for severe COVID-19. TRIAL REGISTRATION: Chinese Clinical Trial Registration; ChiCTR2000031494; Registered on 2 April 2020; http://www.medresman.org
has issue date	2020-08-18(xsd:dateTime)
bibo:doi	10.1186/s13287-020-01875-5
bibo:pmid	32811531
has license	cc-by
sha1sum (hex)	423d6f7230d739099d53c655840ab031e4c3ec68
schema:url	https://doi.org/10.1186/s13287-020-01875-5
resource representing a document's title	Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells
has PubMed Central identifier	PMC7432540
has PubMed identifier	32811531
schema:publication	Stem Cell Res Ther
resource representing a document's body	covid:423d6f7230d739099d53c655840ab031e4c3ec68#body_text
is schema:about of	named entity 'Background' named entity 'COVID-19' named entity 'respiratory disease' named entity 'highly' named entity 'severe' named entity 'mesenchymal stem cells' named entity 'immunogenicity' named entity 'Declaration of Helsinki' named entity 'exogenous' named entity 'resting state' named entity 'treatment group' named entity 'standard treatment' named entity 'control group' named entity 'lymph node enlargement' named entity 'chest tightness' named entity 'laboratory tests' named entity 'COVID' named entity 'critical illness' named entity 'interquartile range' named entity 'host cell' named entity 'subpleural' named entity 'COVID' named entity 'weakness and fatigue' named entity 'CD34' named entity 'diabetes' named entity 'epidemic' named entity 'Mann-Whitney U test' named entity 'GGO' named entity 'sample size' named entity 'COVID' named entity 'Medical Research' named entity 'standard deviation' named entity 'shortness of breath' named entity 'CT imaging' named entity 'epithelial cells' named entity 'infection' named entity 'critical illness' named entity 'ordinal scale' named entity 'experimental design' named entity 'COVID' named entity 'Shaanxi Province' named entity 'normal saline' named entity 'inflammatory factors' named entity 'gap junctions' named entity 'antibacterial drugs' named entity 'control group' named entity 'COVID' named entity 'inflammatory response' named entity 'MSCs' named entity 'intravenous drip' named entity 'mesenchymal stem cells' named entity 'mesenchymal stem cells' named entity 'older age' named entity 'ordinal scale' named entity 'CT scans' named entity 'Wuhan City' named entity 'global health' named entity 'shortness of breath' named entity 'laboratory test' named entity 'treatment and control groups' named entity 'ARDS' named entity 'MSCs' named entity 'CD105' named entity 'COVID' named entity 'CD14'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software